Gaohua Lu Interplay of permeability, metabolism, transporters, and dosing in determining the dynamics of tissue/plasma partition coefficient (Kp) and volume of distribution (Vd) – a theoretical investigation using permeability-limited physiologically-based pharmacokinetic (PBPK) modeling
|
Integrating Dynamic in vitro Systems and Mechanistic Absorption Modelling: Case Study of Pralsetinib
|
Ahmed Elmokadem Bayesian PBPK Modeling using R/Stan/Torsten and Julia/SciML/Turing.jl
|
Charles Chen Physiologically Based Pharmacokinetic (PBPK) Model Of Sparsentan To Evaluate Drug-Drug Interaction Potential
|
Xinwen Zhang Physiologically Based Pharmacokinetic Modeling to Predict Adult and Pediatric Pharmacokinetics of Bispecific T Cell Engager Antibodies for Solid Tumor Indications
|
Development of a Minimal Physiologically-Based Pharmacokinetic (mPBPK) Model to Predict MEN1703 Tissue Distribution in Humans
|
Annie Albin Melba Lumine Lumen Physiologically Based Pharmacokinetic Modeling to Predict Human Ocular Pharmacokinetics and Ocular Toxicity of Systemically Administered Anticancer Therapeutic Proteins for Dosing Regimen Optimization in Oncology Patients
|
Chandrali Bhattacharya Physiologically-Based Pharmacokinetic (PBPK) Model Development and Validation of AZD4831 and Application to Predict Drug-Drug Interaction with CYP3A4 Substrate
|
Brian Cicali Leveraging Physiologically Based Pharmacokinetic (PBPK) Modeling to Explore the Role of OCT1 on Tramadol and its Active Metabolite Exposure in Healthy Adults and Children
|
Determination of the Number of Tissue Groups with Kinetically Distinct Transit Times in Whole-body Physiologically-Based Pharmacokinetic (PBPK) Models: Theoretical Consideration of Bottom-Up Approach to Lumping Tissues in Whole-body PBPK
|
Gregory Ferl Virtual population and non-linear mixed-effects approaches to mechanistic hypothesis exploration of a physiologically-based ocular model to support preclinical and clinical drug development
|
Naveed Shaik A Physiologically Based Pharmacokinetic Model of Long-Acting Lenacapavir
|
PBPK modelling relates subcutaneous bioavailability of mAbs to the saturation of FcRn-mediated recycling in dosing site draining lymph nodes
|
Evaluation of drug-drug interaction between rilpivirine and daily/weekly rifapentine through physiologically based pharmacokinetic (PBPK) modelling
|
PBPK Models for OCT2 and MATE Interaction Predictions: A Drug-Biomarker Interaction Network of Creatinine, N1-Methylnicotinamide, Trimethoprim, Pyrimethamine and Cimetidine
|
The Impact of UGT2B7 and CYP2D6 Gene-Drug- and CYP-mediated Drug-Drug-Interactions on Oxycodone and Oxymorphone Pharmacokinetics using PBPK Modelling
|
XIAONAN LI Liver-to-Plasma Partition Coefficients and In Silico Calculation Methods Differ with Hepatic Clearance Models
|
Development of a Physiologically Based Pharmacokinetic (PBPK) Model for Pexidartinib to Evaluate the Impact of Meal Contents and Intake Timing on Drug Exposure
|
Leyanis Rodríguez Vera Applying Physiologically-Based Pharmacokinetic (PBPK) Modeling to Assess Complex Metabolic-Mediated Drug-Drug Interactions (DDIs).
|
Lais Wright Development and Validation of a Whole-body PBPK Model of Drospirenone for Drug-drug Interaction Studies
|
Daunorubicin PBPK model in Lean and Overweight Children
|
Jia Zhou Application of a Physiologically-Based Pharmacokinetic (PBPK) Model to Predict the PK of Monoclonal Antibodies in Pediatric Subjects
|
Dwaipayan Mukherjee Assessment of Drug-Drug Interactions of Navitoclax in Cancer Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations
|
Parsshava Mehta Application of interspecies PBPK modeling to characterize BBB permeability using levetiracetam and acetaminophen as model drug
|
Vivaswath Ayyar Minimal physiologically-based pharmacokinetic (mPBPK) metamodeling of target engagement in psoriatic skin
|
Zoe Kane Benznidazole pharmacokinetics in adults and children: Application of PBPK modeling to explore the impact of age on benznidazole pharmacokinetics.
|